Beigene Ltd
ONC326.060USD
-2.650-0.81%
Close 09/26, 16:00（ET）Quotes delayed by 15 min
32.94BMarket Cap
LossP/E TTM
More Details of Company
Company Info
Ticker SymbolONC
Company nameBeOne Medicines AG
IPO date- -
CEOMr. John Victor Oyler
Number of employees11000
Security typeOrdinary Share
Fiscal year-end- -
Addressc/o BeOne Medicines I GmbH
CityBASEL
Stock exchangeThe Toronto Stock Exchange
CountrySwitzerland
Postal code4051
Phone41616851900
Website
Ticker SymbolONC
IPO date- -
CEOMr. John Victor Oyler
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Xiaobin Wu, Ph.D.
Mr. Xiaobin Wu, Ph.D.
President, Chief Operating Officer, General Manager, China
President, Chief Operating Officer, General Manager, China
10.89K
--
Mr. Lai Wang
Mr. Lai Wang
Global Head of R&D
Global Head of R&D
--
--
MR. Aaron Rosenberg
MR. Aaron Rosenberg
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Olivier Brandicourt, M.D.
Dr. Olivier Brandicourt, M.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Giancarlo Benelli
Mr. Giancarlo Benelli
Senior Vice President, Head of Europe
Senior Vice President, Head of Europe
--
--
Mr. Chan Lee, J.D.
Mr. Chan Lee, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
--
--
Ms. Shalini Sharp
Ms. Shalini Sharp
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Xiaodong Wang, Ph.D.
Dr. Xiaodong Wang, Ph.D.
Co-Founder, Non-Executive Director
Co-Founder, Non-Executive Director
--
--
Dr. Han (Margaret) Dugan, M.D.
Dr. Han (Margaret) Dugan, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. John Victor Oyler
Mr. John Victor Oyler
Co-Founder, Executive Chairman of the Board, Chief Executive Officer
Co-Founder, Executive Chairman of the Board, Chief Executive Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Xiaobin Wu, Ph.D.
Mr. Xiaobin Wu, Ph.D.
President, Chief Operating Officer, General Manager, China
President, Chief Operating Officer, General Manager, China
10.89K
--
Mr. Lai Wang
Mr. Lai Wang
Global Head of R&D
Global Head of R&D
--
--
MR. Aaron Rosenberg
MR. Aaron Rosenberg
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Olivier Brandicourt, M.D.
Dr. Olivier Brandicourt, M.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Giancarlo Benelli
Mr. Giancarlo Benelli
Senior Vice President, Head of Europe
Senior Vice President, Head of Europe
--
--
Mr. Chan Lee, J.D.
Mr. Chan Lee, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
--
--
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Product
1.09B
97.61%
BRUKINSA
791.66M
70.86%
Tislelizumab
171.16M
15.32%
XGEVA
70.42M
6.30%
BLINCYTO
23.91M
2.14%
Other
-1.03B
-92.23%
By RegionUSD
Name
Revenue
Proportion
United States
567.21M
50.77%
China
399.59M
35.76%
Europe
118.55M
10.61%
ROW
31.92M
2.86%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Product
1.09B
97.61%
BRUKINSA
791.66M
70.86%
Tislelizumab
171.16M
15.32%
XGEVA
70.42M
6.30%
BLINCYTO
23.91M
2.14%
Other
-1.03B
-92.23%
Shareholding Stats
Updated: 18 hours ago
Updated: 18 hours ago
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Amgen Inc
17.27%
Baker Bros. Advisors LP
8.02%
PRIMECAP Management Company
4.64%
Capital International Investors
4.45%
Fidelity Management & Research Company LLC
3.11%
Other
62.50%
Shareholders
Shareholders
Proportion
Amgen Inc
17.27%
Baker Bros. Advisors LP
8.02%
PRIMECAP Management Company
4.64%
Capital International Investors
4.45%
Fidelity Management & Research Company LLC
3.11%
Other
62.50%
Shareholder Types
Shareholders
Proportion
Investment Advisor
18.07%
Corporation
17.28%
Hedge Fund
9.62%
Investment Advisor/Hedge Fund
4.28%
Sovereign Wealth Fund
1.13%
Research Firm
0.63%
Bank and Trust
0.07%
Pension Fund
0.05%
Family Office
0.02%
Other
48.85%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
558
63.29M
57.54%
+456.15K
2025Q1
585
69.06M
63.84%
+3.36M
2024Q4
575
70.01M
71.38%
+1.65M
2024Q3
603
67.03M
68.90%
-2.04M
2024Q2
601
66.99M
69.35%
-2.19M
2024Q1
621
66.56M
67.86%
-955.35K
2023Q4
626
65.12M
66.49%
-3.71M
2023Q3
632
67.27M
67.88%
-2.05M
2023Q2
655
66.79M
67.58%
-3.13M
2023Q1
655
67.68M
71.16%
-4.10M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Amgen Inc
18.94M
17.28%
--
--
Feb 20, 2025
Baker Bros. Advisors LP
8.80M
8.03%
--
--
Mar 31, 2025
PRIMECAP Management Company
5.06M
4.61%
-43.40K
-0.85%
Mar 31, 2025
Capital International Investors
5.09M
4.64%
-1.02M
-16.72%
Mar 31, 2025
Fidelity Management & Research Company LLC
3.36M
3.07%
+1.58M
+88.38%
Mar 31, 2025
HHLR Advisors, Ltd.
1.03M
0.94%
--
--
May 09, 2025
Temasek Holdings Pte. Ltd.
993.75K
0.91%
-531.58K
-34.85%
Mar 31, 2025
T. Rowe Price International Ltd
1.30M
1.19%
-143.22K
-9.92%
Mar 31, 2025
Citadel Advisors LLC
982.16K
0.9%
+665.05K
+209.72%
Mar 31, 2025
Invus Public Equities Advisors, LLC
498.69K
0.46%
-155.03K
-23.72%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Sep 6
Updated: Sat, Sep 6
Name
Proportion
Goldman Sachs MarketBeta Emerging Markets Eqty ETF
0%
Goldman Sachs Innovate Equity ETF
0%
Goldman Sachs MarketBeta Total Internatl Eqty ETF
0%
T Rowe Price Small-Mid Cap ETF
0%
T Rowe Price US Equity Research ETF
0%
Invesco ESG NASDAQ Next Gen 100 ETF
0%
Invesco NASDAQ Next Gen 100 ETF
0%
Goldman Sachs MarketBeta Emerging Markets Eqty ETF
Proportion0%
Goldman Sachs Innovate Equity ETF
Proportion0%
Goldman Sachs MarketBeta Total Internatl Eqty ETF
Proportion0%
T Rowe Price Small-Mid Cap ETF
Proportion0%
T Rowe Price US Equity Research ETF
Proportion0%
Invesco ESG NASDAQ Next Gen 100 ETF
Proportion0%
Invesco NASDAQ Next Gen 100 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
